The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has voted to broaden its guidance for respiratory syncytial virus (RSV) vaccinations, now recommending them for adults aged 50-59 who are at heightened risk of RSV-related lower respiratory tract disease. This recommendation includes the use of Pfizer's vaccine, ABRYSVO, which the U.S. Food and Drug Administration approved in October 2024 for individuals aged 18 to 59 at risk of severe RSV disease.
Each year, RSV causes approximately 15,000 to 20,000 hospitalizations in U.S. adults aged 50 to 59, according to the CDC. Adults with health conditions such as obesity, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, asthma, or other chronic or immunocompromising conditions face the greatest risk of hospitalization due to RSV.
This recent ACIP recommendation lowers the vaccination age from 60 to 50 for high-risk adults in order to better protect this vulnerable demographic. The recommendation is awaiting final approval from the CDC's director and the Department of Health and Human Services. If approved, it would potentially enhance preventative measures for thousands at risk of severe RSV outcomes.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 19 analysts, the average target price for Pfizer Inc (PFE, Financial) is $29.97 with a high estimate of $41.43 and a low estimate of $23.00. The average target implies an upside of 35.98% from the current price of $22.04. More detailed estimate data can be found on the Pfizer Inc (PFE) Forecast page.
Based on the consensus recommendation from 23 brokerage firms, Pfizer Inc's (PFE, Financial) average brokerage recommendation is currently 2.6, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Pfizer Inc (PFE, Financial) in one year is $28.62, suggesting a upside of 29.85% from the current price of $22.04. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Pfizer Inc (PFE) Summary page.
